【4565】そーせいG 451 【Sosei Heptares Prize for Biophysics, Awards Lecture: 7/12】
■ このスレッドは過去ログ倉庫に格納されています
何度も何度も
「もう来ない！」
宣言するのがルサンチメンズ（笑） キーエンス信用買い残増えすぎ
信用返済期日ギリギリ
早よなゲロ M1もM4も失敗を織り込んでいる株価だからな
仮に失敗のアナウンスがあってもそんなに下がらないだろ 創薬の失敗率考えたら今あるパイプラインが全滅してもおかしくないし、
それ込みの株価だろ。
ただその中でも失敗率の低い方法と銘打ってるんだから、ひとつ位モノにしてもいいかなって感じだが。 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
Heptares is based the New Research Facility (Steinmetz Building) of Granta Park (Cambridge) from August 2018.
・・・
※Heptares: Download Corporate Presentation: "2018.06.08 Corporate Presentation (Sosei Group Corporation Corporate Presentation June 2018)". (6/8up)
※Heptares: Congratulations to our founder Richard Henderson, named a Companion of Honour in the Queen's Birthday Honours list. (Dr Henderson said that “it is a great honour to join such a distinguished group of people from all walks of life”). (6/8)
※IPKat: Kymouse's stay of execution; Stay of injunction: Kymab requested that it may be allowed to continue to supply antibody producing cells for the purpose its collaborations with the the Heptares. (6/11)
※Pluristem Reports: Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study: PLX-PAD treatment reduced risk of revascularization and improved patients’ mobility. (6/12)
※欧州特許出願(Heptares)："Muscarinic Agonists (EP3331528 A1 EP3331529 A1 EP3331869 A1)". (6/13公開) ※欧州特許出願(Heptares)："Mutant GPCRS". (6/13公開)
※ClinicalTrials: Ultibro(Phase3): "Concept2 Inhaler: Digital Adherence System": A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging. Change Study Start: "2018/7/16" (6/13update)
※ClinicalTrial: Phase 1b, FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil±Memantine) for the Treatment of Participants with Mild to Moderate AD: Change Start: "2018/7/30", Add Research Sites. (6/14update)
※NovAlix Biophysics in Drug Discovery 2018: "Structural Insight into Allosteric Modulation of GPCRs": Miles Congreve, Heptares. (6/14 Presented)
※Heptares: "Receptionists - Jobshare (25 hours per week)": We are now seeking to recruit two highly motivated part-time receptionists to join the Operations team. (6/15up)
※EHA: "MTL-CEBPA, a Small Activating RNA for Intravenous Administration to Enhance C/EBPΑ Expression in Patients with Liver Cancer Shows Potential Use in Neutropenia": Choon Ping Tan, MiNA Therapeutics. (6/16 Presented)
※Pluristem: U.S. Department of Defense to Study Pluristem’s PLX-R18 for the Treatment of Mustard Gas Injuries Studies to be funded by the U.S. NIH Marks the second project for DOD with PLX-R18 cell therapy product. (6/19) ※Nature: "Cryo-EM structure of the serotonin 5-HT1B receptor coupled to heterotrimeric Go": Christopher G. Tate (MRC Laboratory of Molecular Biology). This work was funded by the Heptares Therapeutics. (6/20up)
※RCSB Protein Data Bank: (Structure ID: 6G79): "Coupling specificity of heterotrimeric Go to the serotonin 5-HT1B receptor": (Released: 2018/6/20) (6/20up)
※MRC LMB: Uncovering the structure of the serotonin receptor. Scientists in Chris’ group purified the serotonin receptor (a GPCR) and combined it with the individual purified components of an engineered Go protein to recreate the signalling complex. (6/21)
※Heptares: "Senior Scientist - Molecular Pharmacology": Strengthen and expand its capabilities in the immunology/inflammation therapeutic areas, now seek to recruit a laboratory-based in vitro pharmacologist to join our Molecular Pharmacology team. (6/21Closed)
※Heptares: "Scientist/Research Scientist - Molecular Pharmacology": Strengthen and expand Molecular Pharmacology team and, now seeking to recruit laboratory-based in vitro pharmacologists. (6/21Closed)
※SOSEI定時株主総会事業報告：「当社事業の飛躍的な拡大」：COPDフランチャイズ売上は順調推移・複数の共同開発プログラム保有・自社PLの迅速な拡充。日本から世界へ：新たなグローバルブランドへ統一：2018年内に運用開始。(6/22) (SOSEI個人投資家説明会(名古屋・大阪)：6/25)
※British Biophysical Society (BBS): 2018 Sosei Heptares Prize for Biophysics: Professor Elspeth Garman, University of Oxford is the first recipient of the 2018 Sosei Heptares Prize for Biophysics from the BBS. (6/22)
・Elspeth is being awarded the prize for her outstanding contributions to our understanding of radiation damage, which has contributed to the improvement of X-ray crystallography and structural biology.
・The Prize will be presented to Professor Garman after her Prize Lecture at the British Biophysical Society Biennial Meeting at University of Southampton (11-13 July, 2018)
"BBS Sosei Heptares Prize for Biophysics":
・The BBS Sosei Heptares Prize for Biophysics was endowed in 2018 by several individual biophysicists who had early involvement with, or were Founders of, Heptares Therapeutics Ltd. (subsequently acquired by Sosei Co. Ltd.) in association with the British Biophysical Society.
・Frequency of award: The Prize will be awarded every two years at the BBS biennial meeting or another BBS meeting.
・Condition of award: The recipient must present a plenary lecture, preferably at the next BBS biennial meeting, but possibly at another BBS meeting within a year of the award.
・Value of the Prize: The recipient will receive £5000. In addition, reasonable travel costs, accommodation and registration to attend the BBS biennial meeting at which the Prize is awarded, will be paid.
・Criteria and eligibility: The Prize will be awarded for substantial contributions to Biophysics or Biophysical Methods by an individual whose principal work has been carried out in the UK or Ireland. ※JITSUBO_HPリニュアル更新：「高品質で低コストなペプチド医薬品の提供を通じ、世界の健康文化の向上に貢献します。」：受託合成サービス(ペプチド合成に関する受託業務)紹介。(6/25)
※City of Hope: Researchers Use Nanoparticles to Test Treatment for Liver Disease. Promising Results: Promising Results: In the study, saRNAs were encapsulated in SMARTICLES nanoparticles to deliver a treatment called MTL-CEBPA in multiple liver disease models. (6/25)
※欧州特許(Heptares)：Bicyclic AZA Compounds as Muscarinic M1 Receptor Agonists. (6/27公開)
※米国特許出願(Heptares)：Bicyclic AZA Compounds as Muscarinic M1 Receptor and/or M4 Receptor Agonists. (6/28公開)
※Adrenoreceptors 2018 (静岡県), Receptor Structure Changes the Pharmacology Paradigm: "Structural insight driving commercial drug discovery": Rob Cooke, Heptares. (6/28 Presented)
※LSX CEO Forum: Case Studies and Peer Review: "Sosei - AZ immune-oncology collaboration" - Malcolm Weir, Chief R&D officer, Sosei (CEO Heptares) (Invited). (6/28 Presented)
※Trial Profile: A randomized, double-blind, placebo controlled, dose ranging study to assess the safety, tolerability, and efficacy of HTL0018318 in patients with dementia with Lewy bodies: JapicCTI-183989(ja)：(予定試験期間：2018/6/1〜2020/7/31、被験者募集状況：募集前、日本). (6/28update)
※医薬品原料国際展in-Pharma Japan (JITSUBO出展6/27~6/29)・技術セミナーも開催「新規ペプチド原薬製造法の開発」：液相、固相合成法に続く第3世代のペプチド合成技術Molecular Hivingの創薬研究および原薬製造への適用と、更なる進化への取り組み紹介。(6/29)
※ClinicalTrials(NCT03381274): Phase 1b/2, Oleclumab(MEDI9447) EGFRm NSCLC Novel Combination Study. (MEDI9447 with Osimertinib or AZD4635, AZD4635 with MEDI9447). (6/29update)
※大阪大学大学院医学系研究科：「認知症プレシジョン医療開発学」寄附講座(教授：森原剛史)開講。発症メカニズムの分子レベルの解明とバイオマーカーの開発、認知症サブグループに対する効率的な治療法開発を目指す。臨床と分子生物学の両分野に強い阪大精神科の強みを活かすための講座。(7/1)
※Labiotech.eu: "13 Biotech Leaders You Should Know in the UK’s Golden Triangle": "Malcolm Weir, Founder & CEO, Heptares", Very successful Biotech based bit outside of London and active in the space of GPCRs. (7/2)
※Department of Biochemistry at the University of Oxford: "2018 Sosei Heptares Prize for Biophysics to be awarded to Professor Elspeth Garman (Department of Biochemistry, University of Oxford). The Prize will be presented at the British Biophysical Society Biennial Meeting. (7/2)
※WCP2018, Kyoto: "PLX-R18- Placenta-derived Mesenchymal-like Stromal Cells are efficacious in reducing lethality in Gastrointestinal Acute Radiation Syndrome (GI-ARS) Mouse Model": Fukushima Medical University (Pluristem). (7/3 Presented)
※The Big Bang Fair Eastern 2018, University of Hertfordshire: The Big Bang Fair Eastern2018 Prize Winners: "Students' Award (Sponsored by Heptares) (£100 cash prizes)": "The Chinese Flame Licker Engine": Flegg High Ormiston Academy, Martham, Norfolk. (7/5) ※MiNA Therapeutics_HP: Renewal. "Development Programs" update. (7/3up) ※MiNA Therapeutics: Exited to launch our new website. Head minatx.com to learn more about small activating RNA medicines. (7/6)
※WCP2018, Kyoto: "Biased apelin receptor agonists for cardiovascular disease": Anthony P. Davenport, University of Cambridge, UK, (Heptares ORBIT Projects). (7/6 Presented)
※Heptares: "Receptionists - Jobshare (25 hours per week)": We are now seeking to recruit two highly motivated part-time receptionists to join the Operations team. (7/6 Closed)
※Heptares: We are now seeking to appoint an enthusiastic and motivated “IT Support Technician” working in our expanding IT team. (7/9up, 7/30Closing)
※Pluristem: Signs Collaboration Agreement With Thermo Fisher Scientific: Advance fundamental knowledge of cell therapy industrialization and to improve quality control of the end-to-end supply chain. "A potential to advance the industry significantly" (7/9)
※日本核酸医薬学会第4回年会 博多：Oligonucleotide Therapeutics Societyシンポジウム：OTS-1："MTL-CEBPA has efficacy in a broad range of liver disease models and encouraging early clinical data in a Phase 1 trial in HCC": MiNA Therapeutics. (7/11 Presented)
※British Biophysical Society (BBS) Biennial Meeting: Sosei Heptares Prize for Biophysics: "X-rays in, X-rays out, structure-function not in doubt ": Elspeth Garman, University of Oxford. (7/12 16:30 Awards Lecture)
・・・
※Early Career Scientist Forum on GPCR Signal Transduction (ECSF-GPCR): Ali Jazayeri, Heptares. (7/11-14)
※Novartis Q2 2018 Results: (7/18)
※AstraZeneca H1 and Q2 2018 Results: (7/26)
※Allergan Q2 2018 Results: (7/26)
※大日本住友製薬2019年3月期 第1四半期決算発表：(7/27)
※Medicinal Chemistry GRC: "Novel Adenosine 2A Receptor Antagonist AZD4635: From the Brain to the Tumor Microenvironment": Michelle Lamb, AstraZeneca USA. (8/6 9:45)
※あすか製薬 平成31年3月期第1四半期決算発表：(8/6)
※SOSEI 2018年12月期第2四半期決算発表：(8/9)
※ペプチドリーム 平成30年6月期決算発表: (8/9)
・・・ ※SOSEIの成長相場の動向：[株式4分割：(6/27)分割比率修正済]
2010/12/30 (終値_338) ・(2010/10/15※最安値_163、2010/12/27最高値_437)
2011/12/30 (終値_318) ・(2011/_3/15※最安値_173、2011/_6/30最高値_420)
2012/12/28 (終値_522) ・(2012/_6/_6※最安値_238、2012/_9/_7最高値_742)
2013/12/30 (終値1079) ・(2013/_1/_4※最安値_513、2013/_5/_7最高値1525)
2014/_4/25 (終値_515) 売残高144800 買残高_4212800 ・(2014/_4/22最安値_464)※[成長回収期の入口]ステージへ
2015/_2/20 (終値_945) 売残高_56800 買残高_6123200 ・(2015/_3/16最安値_713)※Heptares [成功の序章ステージ]
2015/10/30 (終値1080) 売残高_45600 買残高_8871600 ・(2015/_9/24安値_888)※米国承認[次なる飛躍ステージへ]※[上抜け圏へ]
2016/_4/25 (終値5808) 売残高159200 買残高13619600 ・(2016_5/_9最高値6545)※Allergan[強気相場]
2016/_6/24 (終値3680) 売残高_42000 買残高_9944400 ・(2016/_6/24安値3240)※[強気相場解除]※[時間軸での調整局面へ]
2017/_3/31 (終値2720) 売残高_22400 買残高10487200 ・(2017/_4/_4安値2570)※[時間軸調整は順調に推移]※[振るい場・拾い場へ]
2017/_9/_8 (終値2175) 売残高__7600 買残高_8151200 ・(2017/_9/_6最安値2147)※[拾い場も順調に推移]
2018/_1/26 (終値3053) 売残高__3600 買残高_5716400 ・(1/22安値2740)※[振るいも順調に推移]
2018/_3/_9 (終値2378) 売残高_42000 買残高_7177600 ・(3/_5安値2195)※[悪地合いにて再びの拾い場へ]
2018/_6/29 (終値1784) 売残高_____0 買残高_7931600 ・(6/26安値1663)※空売り価格規制トリガー抵触(5/11安値1665, 6/5安値1695)
2018/_7/_6 (終値1387) 売残高__7300 買残高_7728300(-203300)※7/10up・※空売り価格規制トリガー抵触(7/2安値1584, 7/3安値1414) ・(7/5最安値1304[※年初来安])
2018/_7/_9 (終値1412) 5日線乖離(+0.09％) 25日線乖離(-14.17％) 75日線乖離(-23.63％) 200日線乖離(-39.04％) (安値1403)
2018/_7/10 (終値1414) 5日線乖離(+1.09％) 25日線乖離(-13.39％) 75日線乖離(-23.07％) 200日線乖離(-38.85％) (安値1409)
2018/_7/11 (終値1382) 5日線乖離(-0.26％) 25日線乖離(-14.83％) 75日線乖離(-24.39％) 200日線乖離(-40.13％) (安値1342)
2018/_7/12 (終値1414) 5日線乖離(+0.87％) 25日線乖離(-12.32％) 75日線乖離(-22.22％) 200日線乖離(-38.63％) (安値1388)
更なる成長の黎明期にて、強気相場後の時間軸での調整終盤は順調推移。株式4分割。仕掛け。笑。
成長戦略も順調・着実な進展で、次なる展開・進捗が楽しみですね。今回も面白くなりました。笑。 空売り外資が大量に空売りしてるのに上げさせるわけないやん
たまに上がるのは獲物を釣るための騙し上げやしw なしてここまで評価が低いのだろうか？
これだけのパイプラインがあって時価総額1080億円とかあり得ないんだけど
外人が不当に株価を下げて買い集めているんだったら、買い集めが終わるまで浮上しなさそうだな ラクオリアやブランジスタとかみてると、材料さえ出せばアホみたいな上がるな
なんかこうも短期的に暴騰する株を見ていると、材料次第でいつそーせいに順番が回ってきてもええんだよな 下げにしか反応しないってのは下げアルゴしかいねえんだわ
買い主体がまるでいない 過去に爆上げしたゴミカス企業で今思えば「バカじゃねーの」ってのたくさんあると思うけど
そのうちのひとつがここやで >>308
>外人が不当に株価を下げて買い集めているんだったら
いい加減その手の妄想から覚めたら？
無理かw そろそろ横横からズドンと下に売ってくる感じですかね
ボラ下げてからの売り増し
いつものパターン これだけ日経上げてもマイナスで、日経が100円くらい押したら暴落するんでしょ？w だからキーエンス売っとけ
ゴミ持ち越したくないだろ？ 今日のそーせいさん、絶好調杉てワロタ。
あっホルダーさん、 どんまい！ 6500円(26000)からリバらしいリバもなく凄いことになってたんだなここ オリンピックまでに株価10万とか言われてたのにな
株主も関係者も逃げ出しててワロタ >>320
当たり前やろ
地合い良い時に押さえつけといたらあとは地合い悪い時に大暴落やから空売りしがいがあるやろ 2年間ずっとくそまじにくそピーターになってマジにくそ。絶対に買っちゃダメ後悔しまくり ピーターさん可哀想だね。
汚れ役一人で引き受けて。 罵詈雑言を受けるだけで3億貰えるなら替わってやりたいな 26000から5600円とかになるなら、別に4分割いらんかったな 月曜はブライトパスショックに連れ下げで爆下げ確定やな…残念 ※MRC LMB:
・・・
※Structural Biology and Molecular Biophysics: "Cryo-EM structure of the adenosine A2A receptor coupled to an engineered heterotrimeric G protein.": (Chris Tate), Heptares also funded this work. (5/4up)
※The Journal of Biological Chemistry: "Mini G protein probes for active G protein-coupled receptors (GPCRs) in live cells". Heptares Grants MC_U105197215 and EMPSI 339995 (to Chris Tate.). (5/11up)
※RCSB Protein Data Bank: (Structure ID: 6GDG): "Cryo-EM structure of the adenosine A2A receptor bound to a miniGs heterotrimer": (Released: 2018/5/16) (5/16up)
※MRC LMB: The New LMB Building in Cambridge was Officially Opened by Her Majesty The Queen. The Queen spoke at length to LMB group leader, Chris Tate, and was fascinated by the potential for new drug delivery systems. (5/24)
※MRC LMB：Congratulations to Richard Henderson from MRC_LMB on being made a Companion of Honour in the Queen’s Birthday Honours. (6/8)
※BBC NEWS: Nobel laureate joins another exclusive club. Dr Richard Henderson has been made a Companion of Honour in the Queen’s Birthday Honours. The order is a special award held by only 65 people at any one time. (6/8)
※HeptaresTL: Congratulations to our founder Richard Henderson, named a Companion of Honour in the Queen's Birthday Honours list. (6/8)
※Varsity Cambridge: Three Cambridge academics recognised in 2018 Queen’s Birthday Honours List. Awarded the Companion of Honour. Dr Henderson said that “it is a great honour to join such a distinguished group of people from all walks of life”. (6/9)
※MRC LMB: Richard Henderson made Companion of Honour. from the LMB’s Structural Studies Division, has been made a Companion of Honour in the Queen’s 2018 Birthday Honours list, for services to electron microscopy of biological molecules. (6/11)
・Founding of the MRC start-up company Heptares in 2007. Heptares now has - 125 employees and is wholly owned by the Japanese company Sosei, developing new drugs for medically important GPCRs.
※Nature: "Cryo-EM structure of the serotonin 5-HT1B receptor coupled to heterotrimeric Go": Christopher G. Tate (MRC Laboratory of Molecular Biology). This work was funded by the Heptares Therapeutics. (6/20up)
※RCSB Protein Data Bank: (Structure ID: 6G79): "Coupling specificity of heterotrimeric Go to the serotonin 5-HT1B receptor": (Released: 2018/6/20) (6/20up)
※MRC LMB: Uncovering the structure of the serotonin receptor. Scientists in Chris’ group purified the serotonin receptor (a GPCR) and combined it with the individual purified components of an engineered Go protein to recreate the signalling complex. (6/21)
※Daniel J. Scott 13時間前: (Fiona Marshall, Nathan Robertson, Retweet): Cool use of a StaR, a CHESS-stabilized GPCR and MS to investigate GPCR-lipid interactions. (7/12)
↓ ※Nature: "PtdIns(4,5)P2 stabilizes active states of GPCRs and enhances selectivity of G-protein coupling" (7/11up)
Published: 11 July 2018
Abstract
G-protein-coupled receptors (GPCRs) are involved in many physiological processes and are therefore key drug targets1.
Although detailed structural information is available for GPCRs, the effects of lipids on the receptors, and on downstream coupling of GPCRs to G proteins are largely unknown.
Here we use native mass spectrometry to identify endogenous lipids bound to three class A GPCRs.
We observed preferential binding of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) over related lipids and confirm that the intracellular surface of the receptors contain hotspots for PtdIns(4,5)P2 binding.
Endogenous lipids were also observed bound directly to the trimeric Gαsβγ protein complex of the adenosine A2A receptor (A2AR) in the gas phase.
Using engineered Gα subunits (mini-Gαs, mini-Gαi and mini-Gα12)2, we demonstrate that the complex of mini-Gαs with the β1 adrenergic receptor (β1AR) is stabilized by the binding of two PtdIns(4,5)P2 molecules.
By contrast, PtdIns(4,5)P2 does not stabilize coupling between β1AR and other Gα subunits (mini-Gαi or mini-Gα12) or a high-affinity nanobody.
Other endogenous lipids that bind to these receptors have no effect on coupling, highlighting the specificity of PtdIns(4,5)P2.
Calculations of potential of mean force and increased GTP turnover by the activated neurotensin receptor when coupled to trimeric Gαiβγ complex in the presence of PtdIns(4,5)P2 provide further evidence for a specific effect of PtdIns(4,5)P2 on coupling.
We identify key residues on cognate Gα subunits through which PtdIns(4,5)P2 forms bridging interactions with basic residues on class A GPCRs.
These modulating effects of lipids on receptors suggest consequences for understanding function, G-protein selectivity and drug targeting of class A GPCRs.
Acknowledgements:
Christopher G. Tate acknowledges the MRC (MC_U105197215), an ERC Advanced Grant EMPSI (339995) and funding from Heptares Therapeutics. 時価総額100億しかねえゴミブライトが影響するわけねえし MiNA Therapeutics:
・・・
※SOSEI：2018年3月期決算説明会：「戦略プランを着実に実行し2017年度は著しい進捗を達成」。MiNA Therapeuticsにおける開発は順調に進行。(5/10)
・MTL-CEPBAの第1/2a相臨床試験の進捗は良好。MiNAの追加株式取得のオプション行使の判断のタイミングは2018年下半期。
※TIDES: Oligonucleotide and Peptide Therapeutics 2018: "RNA Activation in NASH, Liver Failure and Hepatocellular Carcinoma": Nagy Habib, MiNA Therapeutics. (5/10 Presented)
※MiNA Therapeutics to Present Initial Results from First-in-Human MTL-CEBPA Study at the 2018 ASCO Annual Meeting. MiNA will Announce the Results Through a Press Release Following the Presentation. (5/16)
※ASGCT: "Short Activating RNAs. MTL-CEBPa has a Broad Range of Liver Disease Models and Encouraging Early Clinical Data in a Phase 1 Trial in HCC": Nagy Habib, MiNA Therapeutics. (5/18 Presented)
※SOSEI Presentation: "Sosei Group Corporation, UBS Global Healthcare Conference": Global operations and aspirations - aiming to build Japan’s first global biotech champion: Drive Global Growth Strategy. (5/21Presented, 5/22up)
・Strategic investment in saRNA technology, Exclusive option to move from 25.6% to 100% ownership at pre-determined economics: MiNA Therapeutics.
・Strategic investment in saRNA therapeutics with lead candidate in Phase 1/2a for liver cancer, an orphan indication: MiNA Therapeutics.
※ASCO 2018: "Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA targeting the transcription factor C/EBP-α in patients with advanced liver cancer": MiNA Therapeutics. (6/4 Presented)
※MiNA Therapeutics Presents Initial Results from First-in-Human MTL-CEBPA Study in Advanced Liver Cancer Patients. First look at saRNA therapeutics in patients - Initial results from Phase 1 study of MTL-CEBPA in patients with liver cancer presented. (6/4)
※Robert Habib: A very promising start for saRNA medicines in patients! Looking forward to future development of MTL-CEBPA drug candidate. Dr Sarker from GSTTnhs presenting initial clinical results of MTL-CEBPA today at ASCO 2018. (6/4)
※SOSEI：MiNA Therapeuticsが進行肝がん患者を対象とするMTL-CEBPAの初めてのヒト試験の初期結果を発表：正常肝機能および肝機能障害のある患者において良好な忍容性がみられた。血液検体の解析によりRNA活性機序を実証。薬効標的への作用を確認。(6/5)
※Heptares_HP: Download Corporate Presentation: "2018.06.08 Corporate Presentation (Sosei Group Corporation Corporate Presentation June 2018)". (6/8up)
※Robert Habib: "Benchling" growing (Today, Announce our Series B funding.). We are happy customers. MiNA Therapeutics. (6/15)
※EHA: "MTL-CEBPA, a Small Activating RNA for Intravenous Administration to Enhance C/EBPΑ Expression in Patients with Liver Cancer Shows Potential Use in Neutropenia": Choon Ping Tan, MiNA Therapeutics. (6/16 Presented)
※City of Hope: Researchers Use Nanoparticles to Test Treatment for Liver Disease. Promising Results: Promising Results: In the study, saRNAs were encapsulated in SMARTICLES nanoparticles to deliver a treatment called MTL-CEBPA in multiple liver disease models. (6/25)
※MiNA Therapeutics_HP: Renewal. "Development Programs" update. http://minatx.com/ (7/3up) ※MiNA Therapeutics: Exited to launch our new website. Head minatx.com to learn more about small activating RNA medicines. (7/6)
※日本核酸医薬学会第4回年会 博多：Oligonucleotide Therapeutics Societyシンポジウム：OTS-1："MTL-CEBPA has efficacy in a broad range of liver disease models and encouraging early clinical data in a Phase 1 trial in HCC": MiNA Therapeutics. (7/11 Presented)
・・・
※MiNA Therapeutics 13分前：MiNA research lab very happy with our new western blot machine. Cool technology that gives us better results, faster. ProteinSimple.
ttps://pbs.twimg.com/media/Dh_A3XtX0AAqMGs.jpg ■ このスレッドは過去ログ倉庫に格納されています
